Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Imipramine Pamoate Capsules Generic Name & Formulations
Legal Class
Rx
General Description
Imipramine pamoate (equal to HCl) 75mg, 100mg, 125mg, 150mg.
Pharmacological Class
Tricyclic.
See Also
How Supplied
Contact supplier
Manufacturer
Mechanism of Action
The exact mechanism of action is not known. However, it does not act primarily by stimulation of the central nervous system. The clinical effect is hypothesized as being due to potentiation of adrenergic synapses by blocking uptake of norepinephrine at nerve endings. Its mechanism of action in controlling childhood enuresis is thought to be apart from its antidepressant effect.
Imipramine Pamoate Capsules Indications
Indications
Depression.
Imipramine Pamoate Capsules Dosage and Administration
Adult
Give once a day at bedtime or in divided doses. Outpatients: initially 75mg/day; max 200mg/day. Inpatients: initially 100–150mg/day, max 300mg/day. Adolescents or elderly: start with imipramine HCl tabs 25–50mg/day; usual max 100mg/day. For maintenance doses >75mg, may switch to imipramine pamoate caps.
Children
Not established.
Imipramine Pamoate Capsules Contraindications
Contraindications
During or within 14 days of MAOIs. Concomitant linezolid or IV methylene blue. Acute post-MI.
Imipramine Pamoate Capsules Boxed Warnings
Boxed Warning
Suicidality and antidepressant drugs.
Imipramine Pamoate Capsules Warnings/Precautions
Warnings/Precautions
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes. Monitor for emergence of serotonin syndrome; discontinue if occurs. Screen for bipolar disorder. Cardiovascular disease. Increased intraocular pressure. Urinary retention. Hyperthyroidism. Seizure disorder. Angle-closure glaucoma. Mania/hypomania. Psychosis. ECT. Diabetes. Renal or hepatic impairment. Perform leukocyte and blood counts if fever and sore throat develops. Discontinue prior to surgery or evidence of pathological neutrophil depression. Write ℞ for smallest amount feasible. Elderly. Pregnancy. Nursing mothers: not recommended.
Imipramine Pamoate Capsules Pharmacokinetics
Elimination
Renal. Half-life: 12 hours.
Imipramine Pamoate Capsules Interactions
Interactions
See Contraindications. Increased risk of serotonin syndrome with other serotonergic drugs (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Potentiates alcohol, sympathomimetics (eg, epinephrine, norepinephrine), CNS depressants. Potentiated by methylphenidate, CYP2D6 inhibitors; monitor plasma levels with cimetidine, fluoxetine, quinidine, SSRIs, phenothiazines, type 1C antiarrhythmics (eg, propafenone, flecainide). Antagonized by barbiturates, phenytoin. Paralytic ileus with anticholinergics. Blocks guanethidine, clonidine. Possible cardiotoxicity with concomitant thyroid medications.
Imipramine Pamoate Capsules Adverse Reactions
Adverse Reactions
Drowsiness, anticholinergic effects, CNS overstimulation, arrhythmias, extrapyramidal symptoms, hypo- or hypertension, nausea, fatigue, rash, increased perspiration, headache, changes in blood sugar, photosensitivity, edema, blood dyscrasias (discontinue if occurs), jaundice.
Imipramine Pamoate Capsules Clinical Trials
See Literature
Imipramine Pamoate Capsules Note
Notes
Formerly known under the brand name Tofranil-PM.
Imipramine Pamoate Capsules Patient Counseling
See Literature
